Hosted on MSN6d
FDA lifts clinical hold on Amylyx’s Phase I ALS trial
This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
BioSpace6d
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
FierceBiotech7d
FDA gives Amylyx green light for phase 1 ALS trial after clinical hold
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
biopharma-reporter5d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
bovnews5d
Amylyx Pharmaceuticals Inc (AMLX) Stock’s -0.17% Decrease This Year: What’s the Story?
Amylyx Pharmaceuticals Inc (AMLX) stock saw a decline, ending the day at $3.45 which represents a decrease of $-0.15 or -4.17% from the prior close of $3.6. The stock opened at $3.43 and touched a low ...
Hosted on MSN10mon
Amylyx’s ALS Drug Fails Trial, Raising Questions About Company’s Future
The biotech Amylyx Pharmaceuticals said Friday it will consider pulling its amyotrophic lateral sclerosis, or ALS, drug from the market after it failed to slow progression of the disease in a ...
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of ALS ...
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...
Amylyx Pharmaceuticals Enters Underwriting Agreement for Public Offering
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price ...
Yahoo Finance10d
Amylyx Pharmaceuticals, Inc. (AMLX)
CAMBRIDGE, Mass., January 10, 2025--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of ...
Nasdaq22d
Amylyx appoints Dan Monahan as Chief Commercial Officer
Amylyx (AMLX) Pharmaceuticals announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership Team. Mr. Monahan joined Amylyx in January ...
Wall Street Journal2mon
Amylyx Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...